Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.66 |
| ▸ | NPC1 | O15118 | 5/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | FAAH | O00519 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179015 | 0.88 | RAB9A (0.71) | RAB9ANPC1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL11695764 | 0.86 | RAB9A (0.76) | RAB9ANPC1HPGDALDH1A1PKM | |
| SCHEMBL16085741 | 0.83 | NLRP3 (0.60) | RAB9ANPC1HPGDALDH1A1CYP1A2 | |
| SCHEMBL7237114 | 0.81 | HSD17B10 (0.61) | RAB9ANPC1HPGDALDH1A1CYP1A2 | |
| SCHEMBL4343783 | 0.81 | P2RX4 (0.56) | RAB9ANPC1HPGDALDH1A1CYP1A2 | |
| SCHEMBL21933248 | 0.81 | RAB9A (0.63) | RAB9ANPC1HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL29609862 | 0.81 | P2RY14 (0.69) | RAB9ANPC1HPGDALDH1A1KDM4E | |
| SCHEMBL28352889 | 0.81 | P2RY14 (0.69) | RAB9ANPC1HPGDALDH1A1KDM4E | |
| SCHEMBL8636561 | 0.80 | MAPK8 (0.67) | RAB9ANPC1HPGDALDH1A1CYP1A2 | |
| SCHEMBL8574155 | 0.79 | ALDH1A1 (0.62) | RAB9ANPC1HPGDALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109714-A1 | NEURODEGENERATIVE DISEASE THERAPEUTIC AGENT | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109714-A1 | NEURODEGENERATIVE DISEASE THERAPEUTIC AGENT | SNCA, NLN, GAP43 | RAB9A 924/4885NPC1 508/4885HPGD 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.